Development and validation of DNA methylation scores in two European cohorts augment 10-year risk prediction of type 2 diabetes.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 37117793.
- Also identified by DOI 10.1038/s43587-023-00391-4.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Type 2 diabetes mellitus (T2D) presents a major health and economic burden that could be alleviated with improved early prediction and intervention. While standard risk factors have shown good predictive performance, we show that the use of blood-based DNA methylation information leads to a significant improvement in the prediction of 10-year T2D incidence risk. Previous studies have been largely constrained by linear assumptions, the use of cytosine-guanine pairs one-at-a-time and binary outcomes. We present a flexible approach (via an R package, MethylPipeR) based on a range of linear and tree-ensemble models that incorporate time-to-event data for prediction. Using the Generation Scotland cohort (training set n<sub>cases</sub> = 374, n<sub>controls</sub> = 9,461; test set n<sub>cases</sub> = 252, n<sub>controls</sub> = 4,526) our best-performing model (area under the receiver operating characteristic curve (AUC) = 0.872, area under the precision-recall curve (PRAUC) = 0.302) showed notable improvement in 10-year onset prediction beyond standard risk factors (AUC = 0.839, precision-recall AUC = 0.227). Replication was observed in the German-based KORA study (n = 1,451, n<sub>cases</sub> = 142, P = 1.6 × 10<sup>-5</sup>).
Medical subject headings
- Diabetes Mellitus, Type 2